Answers are grounded in this paper and cite their sources.
Demonstrates improved prediction of recurrence in lung adenocarcinoma patients, suggesting potential for adjuvant therapy.
// Yu-Chung Wu 1, 2, * , Nien-Chih Wei 3, * , Jung-Jyh Hung 1, 2 , Yi-Chen Yeh 4, 5 , Li-Jen Su 6 , Wen-Hu Hsu 1, 2 and Teh-Ying Chou 4, 5, * 1 Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan 2 Department of Surgery, School of Medicine, National Yang-Ming University, Taipei, Taiwan 3 Auspex Diagnostics, Taipei, Taiwan 4 Division of Molecular Pathology, Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan 5 Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan 6 Core Facilities for High Throughput Experimental Analysis, Institute of Systems Biology and Bioinformatics, National Central University, Jhong-Li, Taiwan * These authors contributed equally to this work Correspondence to: Yu-Chung Wu, email: wuyc@vghtpe.gov.tw Keywords: lung adenocarcinoma, recurrence, prediction model, data aggregation, adjuvant therapy Received: February 06, 2017 Accepted: June 28, 2017 Published: July 11, 2017 ABSTRACT Lung cancer mortality remains high even after successful resection. Adjuvant treatment benefits stage II and III patients, but not stage I patients, and most studies fail to predict recurrence in stage I patients. Our study included 211 lung adenocarcinoma patients (stages I–IIIA; 81% stage I) who received curative resections at Taipei Veterans General Hospital between January 2001 and December 2012. We generated a prediction model using 153 samples, with validation using an additional 58 clinical outcome-blinded samples. Gene expression profiles were generated using formalin-fixed, paraffin-embedded tissue samples and microarrays. Data analysis was performed using a supervised clustering method. The prediction model generated from mixed stage samples successfully separated patients at high vs. low risk for recurrence. The validation tests hazard ratio (HR = 4.38) was similar to that of the training tests (HR = 4.53), indicating a robust training process. Our prediction model successfully distinguished high- from low-risk stage IA and IB patients, with a difference in 5-year disease-free survival between high- and low-risk patients of 42% for stage IA and 45% for stage IB ( p < 0.05). We present a novel and effective model for identifying lung adenocarcinoma patients at high risk for recurrence who may benefit from adjuvant therapy. Our prediction performance of the difference in disease free survival between high risk and low risk groups demonstrates more than two fold improvement over earlier published results.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: